BioCardia, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2022. The filing was signed March 29, 2023. This is an annual report, not a quarterly Q4 report. BioCardia is a clinical-stage company developing cell therapies for cardiovascular and pulmonary diseases; it also sells certain delivery and vascular-access products and earns collaboration revenue.
Financial performance and position
| Metric | 2022 | 2021 |
|---|---|---|
| Total revenue | $1.352 million | $1.015 million |
| Net product revenue | $3,000 | $1,000 |
| Collaboration revenue | $1.349 million | $1.014 million |
| Research and development | $8.834 million | $8.558 million |
| Selling, general and administrative | $4.419 million | $5.087 million |
| Operating loss | $11.901 million | $12.630 million |
| Net loss | $11.907 million | $12.623 million |
| Net loss per share, basic and diluted | $0.67 | $0.75 |
| Cash used in operating activities | $10.561 million | $10.366 million |
| Cash and cash equivalents at year-end | $7.363 million | $12.872 million |
- Revenue remained modest and was almost entirely collaboration revenue. Management says collaboration receipts vary with partners’ development activity and deliverables. The filing does not provide a meaningful gross margin figure.
- Operating costs totaled $13.253 million in 2022, versus $13.645 million in 2021. R&D rose modestly, principally with support for the CardiAMP heart failure trial; SG&A declined, mainly due to lower professional fees, stock-based compensation and rent.
- At year-end, current assets were $7.864 million and current liabilities were $3.585 million. Total liabilities were $4.901 million, including operating lease liabilities; the filing does not report conventional borrowings as debt.
- Cash from financing was $5.122 million, primarily from common-stock sales. The company raised about $1.8 million gross through its ATM offering and about $3.4 million net through a December private placement. Shares outstanding increased to 20.08 million from 16.87 million.
- Accumulated deficit was $140.6 million. The auditor issued an unqualified opinion on the financial statements but highlighted substantial doubt about the company’s ability to continue as a going concern. Management said year-end cash was insufficient to fund planned operations beyond Q3 2023 without additional capital.
Material developments and outlook
- CardiAMP heart failure (BCDA-01): Phase III trial had enrolled 119 patients at 20 sites as described in the filing; 10 control patients had crossed over to receive therapy. In August 2022, the DSMB recommended continuing as designed and reported no significant safety concerns. The company proposed an adaptive statistical analysis plan to the FDA in February 2023; any early efficacy readout or reduced enrollment remained contingent on FDA and DSMB review. Randomized results were blinded.
- CardiAMP chronic myocardial ischemia (BCDA-02): Phase III trial was activated at two sites, with two patients treated. The company was working with the FDA on trial design before broader expansion. CMS coverage for eligible IDE-trial services was reported as up to $20,000 per patient.
- Allogeneic NK1R+ MSC programs: FDA approved an IND for a Phase I/II HFrEF trial in December 2022, with first enrollment anticipated in Q2 2023. An ARDS Phase I/II IND was approved in April 2022; the company planned to seek broader eligibility beyond COVID-19-associated ARDS. These milestones were plans, not completed outcomes.
- Other regulatory progress: CardiAMP received FDA Breakthrough Device Designation for heart failure in January 2022. The Sunnyvale facility was certified for manufacturing in 2022. The company was preparing a Japanese regulatory submission, expected after translation in April 2023.
- Funding and risks: Management expected continuing losses and negative operating cash flows and planned to seek additional equity, debt, collaboration or licensing funding. If funding is unavailable, the company may reduce or delay development, relinquish rights, or cease operations. Equity financing may dilute shareholders.
- Subsequent event: Substantially all cash was held at Silicon Valley Bank when it was closed on March 10, 2023. Following U.S. authorities’ announcement that depositors would have access to funds, the company reported transferring substantially all cash to another bank by March 14 and did not expect an impact from the closure.
- Key risks include clinical-trial efficacy, safety, enrollment and timing; uncertain FDA approval requirements for novel cardiac cell therapies; reliance on third parties and suppliers; manufacturing scale-up; reimbursement and commercialization; and the need for further financing. The company reported no current pending legal proceedings it believed likely to have an adverse effect.
Most important facts for investors to verify
- Latest cash, operating burn, financing completed after the filing, and whether the going-concern uncertainty was alleviated.
- FDA feedback and DSMB decisions on the proposed adaptive plan, CardiAMP trial enrollment and primary endpoint results.
- Progress, enrollment and timelines for the CardiAMP CMI and both NK1R+ MSC trials.
- Whether reported trial coverage, manufacturing readiness and regulatory designations translate into viable approval and reimbursement pathways.
- Further share issuance, dilution, and changes in the company’s collaboration revenue or funding arrangements.